Navigation Links
Onyx Pharmaceuticals to Present at the 27th Annual JPMorgan Healthcare Conference
Date:1/5/2009

EMERYVILLE, Calif., Jan. 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12, at 11:00 a.m. Pacific Time. Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar.

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through February 12, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... neural circuits with very high precision light to control cells — optogenetics — ... brain. In the current state of the art, spatially patterned light projected via ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This single ... engineered to radically streamline culture processes, minimize processing time, significantly decrease production ...
Breaking Biology Technology:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):